

The *voice* of the community pharmacist.



Our job is your success.

We deliver advocacy, connections and solutions that enable you and your pharmacy to thrive.



COVID-19 Therapeutics:monoclonal antibodies

Lisa Schwartz, PharmD, RPh Senior Director, Professional Affairs



Providing monoclonal antibodies

- 9th PREP Act amendment "...provides liability immunity to and expands the scope of authority for licensed pharmacists to order and administer select COVID-19 therapeutics..."
 - Applies to EUA, BLA or NDA therapeutics
 - Must be subcutaneous, intramuscular, or oral
 - Pharmacy technicians and interns are also authorized to administer
- REGEN-COV is authorized for subcutaneous administration
- State Health Departments determine where the product goes in their jurisdictions.
 - Pharmacies need to contact the state department of health for information about ordering
 - Distribution, as directed the state health department, is handled by AmerisourceBergen
- Complete an additional CE (required by PREP Act amendment) on administering antibodies
- Review OSHA Emergency Temporary Standard from 6/21/21 (<u>summary</u>)
- Medicare covers administration (by enrolled providers) with no cost share.
- Patient cost share may apply with other health plans. Pharmacies should check eligibility and coverage. Health plans required to cover cost of administering free (for now) product but will determine coverage on the medical or prescription benefit, or both.

Claims for monoclonal antibodies

- Medicare Part B and HRSA Uninsured Program
 - Reach out to billing intermediary to get instructions on using Rx claims
 - Three authorized doses, three product codes (600mg, 1200mg, 2400mg)
 - Four administration scenarios, four administration codes (clinic, home, repeat clinic, repeat home)
 - Part B rate is \$450 and \$750 in the home or residence.
- Medical benefit
 - Health plans will require provider enrollment
 - Reach out to billing intermediary to get instructions on using Rx claims
 - Rates unknown, expect they will vary.
 - Patient cost share may apply, check eligibility and coverage.



Claims for monoclonal antibodies

- Prescription benefit
 - 9/10/21 pre-publication guidance, subject to change, mirrors COVID-19 vaccines
 - Free product: Basis of Cost Determination 15 (Free product at no associated cost)
 - Day supply = 1, quantity = quantity administered
 - Professional Service Code MA (Medication Administered)
 - Incentive amount
 - Place of Service
 - Health plans may choose to cover prescription claims, but are not required to cover prescription claims.



NCPA's coronavirus resources

Info center: https://ncpa.org/coronavirus-information

https://ncpa.org/covid-info-community-pharmacy#mab

Learning center: https://ncpa.thinkingcap.com/

Email: covid@ncpa.org



Lisa Schwartz

Senior Director, Profession Affairs Ischwartz@ncpa.org 703-683-8200

